Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelmnews2022-05-03T18:00:36+00:00May 3rd, 2022|The New York Times|
Lawmakers Dismiss McKinsey’s Apology on Opioid Crisis as ‘Empty’news2022-04-27T22:34:40+00:00April 27th, 2022|The New York Times|
Vaccines for young children are being delayed by incomplete data, a top F.D.A. official suggests.news2022-04-26T23:00:56+00:00April 26th, 2022|The New York Times|
Congress Has to Ask How Much McKinsey Hurt the F.D.A.news2022-04-26T18:56:24+00:00April 26th, 2022|The New York Times|
Pfizer Says Booster Strengthens Immune Response for Children 5 to 11news2022-04-14T22:14:31+00:00April 14th, 2022|The New York Times|
McKinsey Opened a Door in Its Firewall Between Pharma Clients and Regulatorsnews2022-04-13T22:06:06+00:00April 13th, 2022|The New York Times|
New Drug Slashed Deaths Among Patients With Severe Covid, Maker Claimsnews2022-04-11T21:52:16+00:00April 11th, 2022|The New York Times|
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trialsnews2022-04-07T23:32:59+00:00April 7th, 2022|The New York Times|
The F.D.A. Suspends Use of Glaxo Antibody Drug in the U.S.news2022-04-05T22:36:24+00:00April 5th, 2022|The New York Times|
F.D.A. Allows Second Coronavirus Boosters for Everyone 50 and Oldernews2022-03-29T23:44:53+00:00March 29th, 2022|The New York Times|
